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Beta-Blockers in
Syncope: The Jury Is Still Out
Madrid et al. (1) are to be commended for assessing the efficacy of
beta-blockers in neurocardiogenic syncope. Syncope is a common
problem, and beta-blockers are commonly used to attempt to treat
this disorder despite a paucity of randomized data.
Unfortunately, design limitations preclude this study from
providing definitive answers as to the role of beta-blocking drugs in
neurocardiogenic syncope. Previous papers have identified predic-
tors of beta-blocker success, including the presence of tachycardia
during the tilt table test, the need for isoproterenol to induce
syncope, and an acute response to beta-blockers (2,3). By including
a high percentage of tilt-negative patients (60%), the investigators
may have inadvertently diluted a potential treatment effect. The
researchers’ own data in their Figure 2 suggest a differential
response to study medication based upon the result of the tilt table
test. We agree with Madrid et al. (1) that tilt tests are not an ideal
diagnostic modality, but a better tool is not presently available. We
are now validating objective criteria quantitatively for the causes of
syncope that make use of a structured history to diagnose neuro-
cardiogenic syncope (1). Without such a tool, a positive tilt test
remains the diagnostic standard.
In the accompanying editorial to the Madrid et al. (1) article,
Dr. Sra (5) correctly points out that the assessment of therapy in
neurocardiogenic syncope is difficult. A single recurrence of syn-
cope is not an ideal end point due to symptom clusters and long
symptom-free periods. This problem is not unique to syncope
research; it is also seen in other disorders such as paroxysmal atrial
fibrillation. We have previously reported that the time to first
syncope recurrence after a positive tilt table test correlates very well
with the frequency of syncope after a positive tilt table test (6).
Time to first syncope recurrence is an appropriate end point for
such studies, but it can be supplemented with other end points
such as syncope burden and presyncope burden.
We agree with Dr. Sra (5) about the need for a large-scale
multicenter trial to answer the question of beta-blockers for
neurocardiogenic syncope. We are presently conducting a multi-
national, double-blind, placebo-controlled study of oral metoprolol
in patients with at least three lifetime episodes of neurocardiogenic
syncope and a positive head-up tilt table test. In the study, which
is funded by the Canadian Institutes of Health Research, we are
enrolling 220 patients, each of whom will be on blinded therapy for
one year. The primary end point is time to first syncope recurrence,
and secondary end points include the burden of syncope and
presyncope, and the quality of life over the full year.
Madrid et al. (1) may eventually be found to be correct in
concluding that atenolol specifically and beta-blockers in general
are not effective in decreasing or delaying symptoms in patients
with neurocardiogenic syncope. However, the final answer is not
yet known.
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REPLY
We appreciate the interest of Sheldon et al. in our article and the
opportunity to respond to his letter. We are aware of his concerns
regarding the methodology of our study, considering the diagnosis
of vasovagal syncope based on the typical clinical history. We do
not question the great clinical value of the tilt test, but in this
technified medicine we also need to consider the value of simple
things such as the anamnesis and physical examination. We
recognize the progress in the knowledge of physiology, which the
tilt test has rendered, but nevertheless it is not the gold standard
for the diagnosis of vasovagal syncope, with its limited sensitivity
and specificity and its dependence on the protocol.
In our study, only those patients with a clear anamnesis of
vasovagal syncope were included. In fact, more than 700 patients
with unexplained syncope were evaluated, and in the end only 50
patients were eligible for the study, including those patients with
clear clinical history of vasovagal syncope who were highly symp-
tomatic. A complete study to discard other possible causes of
syncope was carried out in all patients. Moreover, there was no new
etiological diagnosis of syncope during the follow-up (1). We want
to emphasize that despite the lack of efficacy of atenolol, the
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median number of syncopal events dropped in both groups during
the follow-up (from 3 to 2 and 0), simply after evaluating them,
performing the tilt table test and explaining the pathogenesis of the
disease. This fact may explain Dr. Sra’s (2) skepticism on the
medical capacity to prove the benefit of any treatment for vasovagal
syncope. This could also be the reason why almost any treatment
that has been tested for the therapy of vasovagal syncope has been
considered to be effective (3). But we do not know whether a
clinical diagnosis, reassuring the patient and explaining to the
patient the postural maneuvers can be enough to provide symp-
tomatic relief in most patients.
We would like to congratulate Sheldon et al. for his efforts in
establishing the role of beta-blockers for the treatment of vasovagal
syncope. We share his frustrations in the treatment of this
disabling and frequent disease. There is no doubt that new
randomized and controlled studies are needed to reach a definitive
answer. We are happy to have raised doubts on the efficacy of the
drugs most commonly used for this pathology.
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Heterogeneity of Response
to Lipid-Lowering Therapy
I read with great interest the article by Penny et al. (1) on changes
in endothelium-dependent vasomotor responses in mildly diseased
coronary arteries after lipid-lowering therapy. In that report, the
investigators studied angiographic responses to acetylcholine (Ach)
along successive 3-mm coronary segments. On average there was a
small improvement in vasoresponsiveness to Ach after lipid-
lowering therapy. Changes in responsiveness correlated with a
marker of oxidized low-density lipoprotein (LDL), but not with
LDL or total cholesterol levels. As the title implies, the researchers
concluded that, overall, lipid-lowering drug treatment reverses
coronary endothelial dysfunction.
Although the reported observations generally support the broad
concept that, on average, lipid lowering in hypercholesterolemic
individuals with atherosclerotic disease can improve endothelial
function, they also appear to suggest a potentially important
additional and perhaps counterintuitive hypothesis: that the coro-
nary vasomotor responses of some patients may actually react
adversely to lipid-lowering therapy. Reiterating the original obser-
vations of El-Tamimi et al. (2), who showed adjacent segments in
the same artery can show vasodilatory and vasoconstrictive re-
sponses, the investigators document an extraordinary heterogeneity
in responses of individual coronary segments to Ach, both at
baseline and after treatment. More remarkable, the changes in
intraindividual coronary artery segment responses after therapy
appear to occur in both directions, with a large number of
segments showing a decline in vasodilation or vasoconstriction at
follow-up. Though the majority of the “most constricted” seg-
ments at baseline demonstrated improved responses at follow-up,
only 4 of the 29 patients showed arteries that lacked some
segmental “deterioration” in function. Judging from Figure 3 in the
Penny et al. (1) study, where individual segment response changes
were plotted, it appears that 40% to 45% of patients showed a
predominantly contrarian response, with more segments showing a
decline in vasomotor responsiveness rather than “improvement.”
Whereas this may represent regression to the mean, the mecha-
nism is unclear. Although the graphical expression of the data
suggests moderation of responses at follow-up, it leaves some
ambiguity with respect to the severity of the deteriorated segmental
responses, and it seems possible that the magnitude of the
heterogeneity may have been underestimated by the methods
employed.
The benefits of lipid-lowering therapy for reducing clinical
events in patients with hypercholesterolemia and coronary artery
disease have been well established. The observations by Penny et
al. (1), as well as the results of the Coronary Artery Reactivity
After Treatment with Simvastatin (CARATS) trial (3), which
failed to show significant improvement in endothelium-dependent
coronary vasomotor and blood flow responses in patients treated
for six months with simvistatin, highlight a degree of complexity
and inter- and intraindividual variability of response to statin
and/or lipid-lowering therapy that is currently poorly understood,
and yet is one that raises important questions. Are these hetero-
geneous responses the result of random variability, or do the data
imply that there is a subgroup of patients whose coronaries may
respond poorly or even adversely to lipid-lowering therapy? Be-
cause the investigators have demonstrated a correlation between
changes in responsiveness and levels of circulating oxidized LDL
(which are not reliably reduced by statin therapy [4]), do the results
imply that oxidized LDL levels may help identify those patients
who are unlikely to show improvement in endothelial function
with lipid-lowering therapy alone, and may need more aggressive
additional treatment? Would the clinical benefit of statin therapy
be greater if we could select likely patient/coronary “responders”
from “nonresponders” or worse, “adverse responders”? Given that
multiple mechanisms may be involved in the benefit of statin
therapy, this interpretation might be overly simplistic. Neverthe-
less, the observations of Penny et al. (1) suggest variability in
coronary responses to lipid-lowering therapy that may be clinically
relevant and warrant further investigation.
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